Navigation Links
Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/6/2009

PRINCETON, N.J., Jan. 6 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) on Tuesday, January 13, 2009. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved in Canada. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

    Contact: Laura S. Choi                   Nichol Ochsner
             Investor Relations              Corporate Communications (media)
             Phone: 609-430-2880, x2216      Phone: 609-430-2880, x2214


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex to Present at the RBC Capital Markets Healthcare Conference
2. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
3. Medarex Announces 2008 Third Quarter Financial Results
4. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
7. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
8. Medarex Announces July 10 Live Webcast of R&D Day Event
9. Medarex to Present at the Jefferies Second Annual Healthcare Conference
10. Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
11. Medarex to Present at the Bank of America 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... Cynvenio Biosystems, Inc. a leader in personalized medicine technology and ... study in partnership with Allentown, PA-based TME Research . The multi-center registry study ... two years with Cynvenio’s ClearID Breast Cancer blood test. The study goal is to ...
(Date:4/27/2017)... ... April 27, 2017 , ... Oncolinx, a spin-out of ... Competition, has truly taken their cancer research out of this world. On April ... Cape Canaveral to the International Space Station’s (ISS) U.S. National Laboratory, managed by ...
(Date:4/27/2017)... ... 27, 2017 , ... Arrowhead Publishers is pleased to announce ... to San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, biotech, ... in the treatment of various types of pain. There are also extended networking ...
(Date:4/27/2017)... ... 27, 2017 , ... Volunteers supported by SPIE, the ... industry professionals in visiting U.S. Congressional offices in Washington, D.C., yesterday to urge ... industry. , This year, National Photonics Initiative (NPI) Congressional Visits Day ...
Breaking Biology Technology:
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
Breaking Biology News(10 mins):